Doxorubicin-induced death in tumour cells and cardiomyocytes: is autophagy the key to improving future clinical outcomes?
Access Status
Authors
Date
2013Type
Metadata
Show full item recordCitation
Source Title
ISSN
Collection
Abstract
Objectives: Doxorubicin, a commonly used frontline chemotherapeutic agent for cancer, is not without side-effects. The original thinking that the drug causes necrosis in tumours has largely given way to its link with apoptosis over the past two decades. Key findings: More recently, major biomarkers such as AMPK, p53 and Bcl-2 have been identified as important to apoptosis induction by doxorubicin. It is Bcl-2 and its interaction with Beclin-1 that has refocussed research attention on doxorubicin, albeit this time for its ability to induce autophagy. Autophagy can be either anticancerous or procancerous however, so it is critical that the reasons for which cancer cells undergo this type of cell biological event be clearly identified for future exploitation. Summary: Taking a step back from treating patients with large doses of doxorubicin, which causes toxicity to the heart amongst other organs, and further research with this drug's molecular signalling in not only neoplastic but normal cells, may indeed redefine the way doxorubicin is used clinically and potentially lead to better neoplastic disease management.
Related items
Showing items related by title, author, creator and subject.
-
Tacar, O.; Indumathy, S.; Tan, M.; Baindur-Hudson, S.; Friedhuber, A.; Dass, Crispin (2015)Objective Doxorubicin (Dox) is a frontline chemotherapeutic against osteosarcoma (OS) that is plagued by side effects, particularly in the heart. The specific objective of this article is to investigate whether low-dose ...
-
Tacar, O.; Indumathy, S.; Tan, M.; Baindur-Hudson, S.; Friedhuber, A.; Dass, Crispin (2014)© 2014 Royal Pharmaceutical Society. Objective: Doxorubicin (Dox) is a frontline chemotherapeutic against osteosarcoma (OS) that is plagued by side effects, particularly in the heart. The specific objective of this article ...
-
Maillet, A.; Yadav, S.; Loo, Y.; Sachaphibulkij, K.; Pervaiz, Shazib (2013)Engagement of the mitochondrial-death amplification pathway is an essential component in chemotherapeutic execution of cancer cells. Therefore, identification of mitochondria-targeting agents has become an attractive ...